Ammar Ahmed Chaudhry MD, Presenter: Nothing to Disclose

Jung Hwoon Edward Yoon MD, Abstract Co-Author: Nothing to Disclose

William Henry Moore MD, Abstract Co-Author: Research Grant, EDDA Technology, Inc Medical Board, EDDA Technology, Inc Research Grant, Galil Medical Ltd Research Grant, Endo Health Solutions Inc

Kenny Lien MD, Abstract Co-Author: Nothing to Disclose

1- Review indications, interventional methods, contraindications, complications, pearls and pitfalls of percutaneous cryoablation. 2- Cryoablation was previously not recommended for perivascular neoplasms due to heat sink effects and potential damage to adjacent organs. We will discuss novel approach to treat these previously "do NOT cryo" lesions and how to minimize potential risks while obtaining an appropriate size ablation zone. 3-  Algorithm to help determine the best treatment modality in managing lung masses.

A. Anatomy- Effect of cryoablation on vessels, nerves (vagus, phrenic), tracheobronchial tree, esophagus, etc. B. Clinical Findings secondary to mass effect/obstruction  C. Highlight imaging findings (e.g. significance of fat planes) that serve as key to patient inclusion and exclusion criteria. D. Pathophysiology: Cryobiology: Intra- and extracellular mechanisms that promote tumor cell death E. Procedure Technique: discuss key do’s and don’ts e.g. not crossing fissures, not ablating needle tract, etc. F. Follow-up: Immediate post-procedure management and follow-up guidelines G. Outcomes:    a. Complications: Immediate (PTX, hemorrhage, BPF, nerve injury, etc), Delayed (recurrence, BPF, pleural effusions, etc)   b. Survival

http://abstract.rsna.org/uploads/2014/14000238/14000238_byg8.pdf

Chaudhry, A, Yoon, J, Moore, W, Lien, K, Cryoablation of Perivascular Neoplasms: Novel Minimally Invasive Approach to Treat Unresectable Tumors.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14000238.html